Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 1998

View Archived Issues

Seattle Genetics initiates a phase I clinical trial of SGN-10

Phase II trials of Xenova's P-gp pump inhibitor planned in U.S. and U.K.

Vanguard drops hyperphosphatemia Rx from development pipeline

MedImmune and BioTransplant initiate two new clinical studies of MEDI-507

Merck KGaA prefers alliances to mergers; signs new deal with ImClone Systems

Neoprobe to develop product for intraoperative detection of neuroblastoma

FDA grants expedited development status to Cordox as it begins phase III trials

TerraGen and Schering-Plough Research Institute establish collaborative agreement

SmithKline Beecham and Ribi announce positive HBV phase III trial data

Dendreon presents phase I/II data on APC-8020 at ASH meeting

Eisai launches new formulation of antiarrhythmic drug in Japan

SonoRx studies presented at RSNA meeting; U.S. launch imminent

AMI-227: a novel contrast agent with several potential uses in MRI

New RES-specific contrast agents enter the pipeline at Bracco

News from RSNA 98: German team describes MRI contrast agent CMD-Gd-DOTA

Elastase inhibition as a potential approach to treating acute viral myocarditis

Angiotech initiates another clinical trial with paclitaxel for treatment of psoriasis

Tularik, Knoll to collaborate on antiobesity R&D

ISS-DNA alters the immune response and prevents symptoms of allergic asthma

New antidiabetic agents from Yamanouchi have a dual mechanism of action

PLA2 inhibitors with broad potential application as antiinflammatory agents

New agents for micturition disorders discovered at Kyowa Hakko

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...